ArticleJournal of nutrigenetics and nutrigenomics2011
Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis.
Article in Journal of nutrigenetics and nutrigenomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Inverse Association between Omega-3 Index and Severity of COVID-19: A Case-Control Study.International journal of environmental research and public health · 2022Article
- Inflammation Resolution: Implications for Atherosclerosis.Circulation research · 2022Review
- Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response.International journal of molecular sciences · 2020Review
- Mediterranean Diet: Lipids, Inflammation, and Malaria Infection.International journal of molecular sciences · 2020Review
- Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype?Frontiers in pharmacology · 2019Review
- Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2).Journal of the American College of Cardiology · 2018Review
- Pro-resolving lipid mediators in vascular disease.The Journal of clinical investigation · 2018Review
- The role of non-resolving inflammation in atherosclerosis.The Journal of clinical investigation · 2018Review
- Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.Molecular aspects of medicine · 2017Review
- Specialized pro-resolving mediators in cardiovascular diseases.Molecular aspects of medicine · 2017Review
- 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2017Review
- Proresolving Lipid Mediators Restore Balance to the Vulnerable Plaque.Circulation research · 2016Article
- An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.Nature communications · 2016Article
- Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice.The Journal of nutritional biochemistry · 2016Article
- Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.Science translational medicine · 2015Article
- Inflammation and its resolution as determinants of acute coronary syndromes.Circulation research · 2014Review
- Review
- Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.Cell metabolism · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aimPro-resolving and anti-inflammatory mediator products of murine 12/15-lipoxygenase (LOX) exhibit potent actions on vascular inflammation and protect against the progression of atherosclerosis. The present study was designed to determine whether augmenting dietary lipids modulates the body's endogenous anti-inflammatory pro-resolving mechanisms and promotes atherosclerosis. METHODS/
resultsWe investigated the biometabolic consequences of variations in lipid mediator biosynthesis using genetic knockout and overexpression models of 12/15-LOX mice fed the commonly used 'Western diet'. Unexpectedly, this high-fat diet annulled the protective actions of 12/15-LOX, and the combination of a Western diet and 12/15-LOX overexpression paradoxically promoted inflammation leading to production of diet-related and 12/15-LOX-dependent blood mediators that differentially activated endothelial cells via expression of ICAM-1. Hyperlipidemia not only affected the biosynthesis of lipoxin A4, a key pro-resolving mediator, but also disrupted the protective pro-resolving function of 12/15-LOX products, and the enzyme pathway no longer protected against atherosclerosis in vivo.
conclusionWe uncovered a novel mechanism whereby a high-fat diet as well as hyperlipidemia disrupt the homeostasis of inflammation resolution. These findings underscore the importance of dietary essential PUFAs and LOX-derived lipid mediators in combination with lipid-lowering agents in the prevention and treatment of atherosclerotic cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.